Testis and ovary explants have been proposed as in vitro screens for identifying potential inhibitors of steroid biosynthesis. The goals of the current study were to optimize the conditions of the two assays, to characterize these assays using several compounds with well-defined endocrine activity, and to compare the responses from the explant assays with an in vivo male battery currently undergoing validation using the Crl:CD BR rat in order to evaluate their utility as test systems for screening unknown compounds for possible steroid biosynthesis inhibition activity. There were two components to the testis/ovary assays: ex vivo and in vitro. The ex vivo component used testes/ovaries from animals dosed with the test compounds in vivo, and the in vitro component used testes/ovaries from control animals. For the testis assays, decapsulated testis explants (50 mg) were placed into glass scintillation vials, ±1.0 IU/ml hCG for 3 h in a shaking water bath (34°C). Following the incubation period, medium was removed, centrifuged, and frozen until assayed for hormone concentrations. A similar procedure was used for the ovary explant assay except that each ovary was incubated separately. The testis explants were evaluated using the following compounds: ketoconazole (KETO), a testosterone biosynthesis inhibitor; aminoglutethimide (AG) (only in vitro) and anastrozole (ANA), aromatase inhibitors; finasteride (FIN), a 5a-reductase inhibitor; 17p-estradiol (17^E2), an estrogen receptor agonist; flutamide (FLUT), an androgen receptor antagonist; ICI-182,780 (ICI), an estrogen receptor antagonist; haloperidol (HALO), a D 2 receptor antagonist; and reserpine (RES), a dopamine depletor. In the ovary assay, AG (only in vitro), ANA, ICI, and HALO (only in vitro) were evaluated. Addition of fetal calf serum to the medium allowed measurement of estradiol (E2) in the testis assay, but production was not inhibited by ANA or AG. In the ovary explant assay, only AG was identified as inhibiting E2 production in vitro. Hence, both the testis and ovary explant assays appear to have limited utility for ' This study was funded partially by the Chemical Manufacturers Association and the Chlorine Chemistry Council, 1300 Wilson Boulevard, Arlington, Virginia, 22209.
Water Act of 1996, which require the United States Environmental Protection Agency (USEPA) to implement screening and testing strategies to identify EACs. The USEPA responded by forming a multistakeholder committee, the Endocrine Disruptor Screening and Testing Advisory Committee (EDSTAC). The purpose of EDSTAC is to recommend to the USEPA a screening and testing strategy for detecting EACs. The implementation of testing is Congressionally mandated to begin in August 1999. EDSTAC has focused its efforts on developing a screening and testing strategy that can identify compounds that are androgenic/antiandrogenic, estrogenic/antiestrogenic, or steroid biosynthesis inhibitors, as well as compounds that alter thyroid hormone function.
The Organisation for Economic Co-operation and Development (OECD) has commissioned a comprehensive survey of test methods for identifying sex-hormone-disrupting chemicals that is currently undergoing comment by the member countries (Holmes et al., 1998) . In addition, several different tiered testing approaches have been proposed for detecting EACs (Reel et al, 1996; Shelby et al, 1996; Ashby et al., 1997; Carney et al., 1997; Cook et al., 1997; Gray et al., 1997) . Common to all these approaches is the combination of in vivo and in vitro assays, recognizing that there are limitations to each approach (reviewed in Gray et al., 1997) . In vivo assays allow integration of ADME principles (adsorption, distribution, metabolism, and excretion) and homeostasis, which are important with highly integrated systems such as the endocrine system, while in vitro approaches are useful for clarifying the site and the mechanism of action. It is clear that no single in vitro or in vivo assay will be able to stand alone as an accurate, sensitive, and cost-effective means to screen and test all potential EACs; however, individual assays may be valuable tools for answering specific questions. For example, testis and ovary explant cultures have been proposed as simple test systems for identifying EACs that alter steroid biosynthesis either through up-or downregulation or via direct inhibition (Gray et al., 1997) . The testis explants are used primarily to identify compounds which inhibit testosterone biosynthesis, while ovary explants are used primarily to identify aromatase inhibitors Berman and Laskey, 1993; Laskey et al., 1994; Piasek and Laskey, 1994; Gray et al., 1995; Laskey et al, 1995) . As proposed, both the testis and ovary explant assays include in vitro and ex vivo (in vivo dosing followed by in vitro assessment of function) assessments. The in vitro assessment can be used to identify compounds that directly inhibit steroid biosynthesis. The ex vivo assessment can be used to identify compounds that up-or downregulate the enzymes of the steroid biosynthetic pathway.
The perceived value of the testis explant culture is primarily based on data generated using isolated Leydig cells (e.g., Klinefelter and Kelce, 1996) . However, to date, the testis explant has been evaluated with only ethane dimethanesulfonate (EDS) Gray et al, 1995) . In contrast, the ovary explant culture has been evaluated with aminoglutethimide (AG) Laskey et al, 1995) , cadmium (Piasek and Laskey, 1994) and di(2-ethylhexyl)phthalate (DEHP) Laskey and Berman, 1993) using ovaries from cycling rats and with cadmium using ovaries from pregnant rats (Piasek and Laskey, 1994) . Because of the limited number of compounds evaluated, as well as the different assay conditions used, the goals of the current study were to optimize the conditions of the two assays, to characterize these assays using several compounds with well-defined endocrine activity, and to compare the responses from the explant assays with an in vivo Tier I male battery currently undergoing validation O'Connor et al, 1998a,b) in order to evaluate their utility as test systems for screening unknown compounds for possible steroid biosynthesis inhibition activity. The rationale for the study design of the Tier I battery undergoing validation has been previously described . The Tier I male battery is designed to identify several different endocrine activities using a comprehensive hormonal assessment coupled with organ weight measurements.
The following EACs were used to evaluate the testis assay: an estrogen receptor agonist (17/3-estradiol, 17/3-E2) (Clark and Markaverich, 1983) , an estrogen receptor antagonist (ICI-182,780, ICI) (Wakeling et al, 1991) , an androgen receptor antagonist (flutamide, FLUT) (Neri et al, 1972; Simard et al, 1986) , a steroid biosynthesis inhibitor (ketoconazole, KETO) (Feldman, 1986) , a selective aromatase inhibitor (anastrozole, ANA) (Dukes et al, 1996) , a mixed aromatase/C^-side chain cleavage inhibitor (AG) (only in vitro) (Salhanick, 1982) , a selective 5a-reductase inhibitor (finasteride, FIN) (Rittmaster, 1994) , a D 2 receptor antagonist (haloperidol, HALO) (Goodman and Gillman, 1996) , and a dopamine depletor (reserpine, RES) (Goodman and Gillman, 1996) . In the ovary assay, AG (only in vitro), ANA, ICI, and HALO (only in vitro) were evaluated. Test species. Male and time-pregnant female (gd 5) Crl:CD BR rats were acquired from Charles River Laboratories, Inc. (Raleigh, NC), and were approximately 63 days of age upon arrival. After a quarantine period of approximately 1 week, male rats designated for Tier I and explant studies that displayed adequate weight gain and freedom from clinical signs were divided by computerized, stratified randomization into five groups of 15 males so that there were no statistically significant differences among group body weight means. Males designated for Leydig cell isolation (n = 12) were also 63 days of age upon arrival and were quarantined for 1 week. Due to study design requirements, pregnant females did not undergo normal quarantine procedures and upon arrival were randomly assigned to study groups so that there were no statistically significant differences among group body weight means (5 rats per group, 5 groups).
MATERIALS AND METHODS
All rats were individually housed in stainless steel, wire-mesh cages suspended above cage boards and were fed irradiated PMI Feeds, Inc., Certified Rodent Diet No. 5002 and provided with tap water (United Water Delaware) ad libitum. Animal rooms were maintained on a 12-h light/dark cycle (fluorescent light), a temperature of 23 ± 2°C, and a relatively humidity of 50 ± 10%.
Study design. All rats were weighed daily and cage-side examinations were performed to detect moribund or dead rats. At each weighing, rats were individually handled and examined for abnormal behavior or appearance. Each test compound was prepared in 0.25% methylcellulose and administered by intraperitoneal injection (2.0 ml/kg body wt) at approximately 0900 h daily. Male rats were dosed for 15 days and euthanized on the morning of test day 15. Pregnant females were dosed for 3 days (gd 6-8) and euthanized on the morning of gd 8. On the day of sacrifice, male and female rats were euthanized approximately 2 h after the last administered dose.
The following dosages were used in the ex vivo experiments with male rats: KETO (25, 50, 75 , and 100 mg/kg/day), ANA (0.1, 0.5, 0.75, and 1.5 mg/kg/day), FIN (1, 5, 10, and 25 mg/kg/day), 17/3-E2 (0.001,0.0025,0.0075, and 0.05 mg/kg/day), FLUT (0.25, 1, 5, and 20 mg/kg/day), HALO (0.1, 0.25, 0.5, and 1 mg/kg/day), ICI (0.05, 0.25, 0.5, and 1 mg/kg/day), and RES (0.1, 0.5, 0.75, and 1 mg/kg). The following dosages were used in ex vivo experiments with pregnant female rats: ICI (0.05, 0.25, 0.5, and 1 mg/kg/day) and ANA (1, 5, 7.5, and 10 mg/kg/day). Doses were selected in order to obtain the maximal pharmacologic effect for each compound and/or not exceed the maximum tolerated dose as determined in range-finder studies.
Concentrations of compounds used in vitro were selected based on limits of solubility (ANA, AG, FIN, HALO, and RES), knowledge of receptor activity (170-E2, ICI, and FLUT), or previous work (KETO) (Biegel et al., 1995) .
Pathology. Male rats were anesthetized using carbon dioxide and euthanized via exsanguination on test day 15 and were evaluated for gross observations of toxicity and organ weights Giver, testes, prostate, seminal vesicles, and accessory sex gland unit). Serum from blood collected at the time of sacrifice was used to measure hormone concentrations: T, E2, dihydrotestosterone (DHT), FSH, leutinizing hormone (LH), prolactin (PRL), thyroidstimulating hormone (TSH), thyroxine (T4), and triiodothyronine (T3). The methods and data are described elsewhere (O'Connor et at, 1998a) and in the accompanying paper (O'Connor et al., 1998b) .
Pregnant female rats were anesthetized using carbon dioxide and euthanized via exsanguination on gd 8. At sacrifice, the number of fetuses in each uterine horn was counted, and both ovaries were removed and cleared of fat.
Testis explant assay. Ex vivo and in vitro analyses of T and E2 production were conducted on five animals from each treatment group. For the ex vivo component, testis explants from animals dosed with 17/3-E2, ICL FLUT, KETO, FIN, ANA, HALO, or RES were cultured with medium containing hCG (1 IU/ml). hCG binds to the LH receptor on Leydig cells to stimulate T production. This stimulation confirms the viability of explants. For the in vitro component, testis explants from untreated animals were cultured with and without hCG (1 IU/ml) and several concentrations of the test compounds. Methods were modified from Laskey and co-workers (1994) to facilitate incorporation into an ongoing validation of a Tier I male screening battery (O'Connor et al., 1998a,b) . Specifically, the amount of testicular parenchyma was reduced from 300-400 mg to 50 mg so the in vitro experiments could be conducted using the control rats from the Tier I male battery. Other measurements (organ weights and serum hormone levels) were made using the same control animals (O'Connor et al, 1998a,b) . One testis per animal was removed, placed in a labeled cassette, moistened with cold physiological saline, placed on ice, and covered with saline-moistened paper towels. The testes were subsequently decapsulated and approximately 50 mg of testicular parenchyma was placed into a 20-ml glass scintillation vial containing 5 ml of culture medium (RPMI-1640 medium, 10% FCS, 50 ^tg/ml soybean trypsin inhibitor) and the appropriate concentrations of the test compounds. The final solvent (DMSO) concentration in the culture media did not exceed 0.2% (v/v). Finally, 10 td of hCG (500 IU/ml stock solution) (or 10 /xl of distilled water for non-hCG stimulated controls) was added, and the vials were capped, briefly vortexed, and incubated vertically for 3 h at 34°C under vigorous shaking (175 rpm). At the end of the incubation period, 1.4 ml of culture medium was removed and centrifuged at 14,000g for 5 min (4°C) to pellet all remaining testicular parenchyma. The resulting supernatant was frozen between -65 and -85°C until analyzed for T and E2 levels.
Leydig cell isolation and culture. Leydig cells from male Crl:CD BR rats were isolated according to the methods of Biegel et al. (1993) . Briefly, the testes were removed from the rats and perfused with a solution of collagenase (1.0 mg/ml) m M-199 medium. The tunicate was removed, and the testes were placed in a digestion medium and shaken in a 37°C water bath for 15 min. The tubules were removed by centrifugation and filtration, and the remaining cells were loaded onto a Percoll gradient and centrifuged at 800g for 30 min. The fraction containing Leydig cells was removed and washed with M-199 medium to remove excess Percoll. Cells were placed in 24-well culture plates at a concentration of 50,000-70,000 cells/well and allowed to attach for 1 h. RPMI 1640 medium (with 10% FCS and 1% antibiotic/antimycotic solution) (500 jxl per well) containing 4 IU/ml hCG and five concentrations of each test compound (0 (±hCG), 0.1, 1, 10, and 100 iiM (all + hCG)) was then added to the wells for 3 h. Culture medium was then removed from the wells and frozen between -65 and -85°C until analyzed for steroid concentrations.
Trypan blue dye exclusion was used to determine cell viability and was performed as follows: 500 /xl of the diluted Leydig cell preparation was combined with 500 jd of 4% trypan blue dye and allowed to incubate for 15 min. Cells were then counted using a hemacytometer and the percentage of viable cells (total unstained cells divided by total cells X 100) was calculated. At the conclusion of the 3-h incubation, cell viability was determined by removing the culture medium from the wells and replacing it with 500 /xl 4% trypan blue dye. Cells were incubated for 15 min, the dye was removed, and six fields were counted using a phase-contrast microscope. The percentage of viable cells was calculated as described above.
Ovary explant assay. Ex vivo and in vitro analyses of E2 and P4 production were conducted on five animals from each group. Methods were modified from Laskey and coworkers (1995) . For the ex vivo component, ovaries from treated pregnant rats (gd 8) were cultured without fleft ovary) and with (right ovary) hCG stimulation (1 IU/ml). For the in vitro component, ovaries from untreated pregnant rats (gd 8) were cultured with medium containing several concentrations of the test compounds and cultured without (left ovary) and with (right ovary) hCG stimulation (1 IU/ml). Ovaries were removed, cleared of fat, placed in labeled cassettes, moistened with physiological saline, and placed on ice until weighed. After weighing, each ovary was placed into a 1.5-ml microfuge tube containing 1 ml of culture medium (RPMI 1640 medium, 10% FCS, 50 /xg/ml soybean trypsin inhibitor) containing the appropriate concentration of test compound Ovaries were thoroughly minced with scissors into approximately <l-mm 3 pieces, and microfuge tubes were vortexed and incubated horizontally for 3 h at 36°C under vigorous shaking (175 rpm). At the end of the incubation period, tubes were centrifuged at 14,000g for 5 min (4°C). The resulting supernatant was frozen between -65 and -85°C until analyzed for E2 and P4 levels.
Spectral binding. In order to determine if HAL and RES inhibit T production via inhibition of cytochrome P450 activity, spectral binding assays were performed according to Lewis (1986) . Liver microsomes from phenobarbital-treated rats were diluted to a concentration of approximately 1 mg protein/ml buffer. Compounds were solubilized in methanol at concentrations production by 50-mg testis explants from control rats incubated in the presence (closed circles) or absence (open circles) of 0.1 IU/ml hCG. Culture medium was removed from the scintillation vials at the appropriate time and analyzed for T and E2 concentrations (n = 2). T levels from hCG-stimulated explants were statistically different from the non-hCGstimulated explants at all time points evaluated (*p £ 0.05).
of 32 mM (HAL) and 0.7 mM (RES) and incubated with microsomes, and the absorbance from 350 to 500 nm was measured.
Statistical analyses. All data are expressed as means ± standard error. All data were analyzed by one-way analysis of variance (ANOVA) except hormonal data. Hormone levels were analyzed using Jonckheere's test for trend. If a significant dose-response trend was detected, data from the top dose group was excluded and the test repeated until no significant trend was detected. Significance was judged atp£ 0.05.
RESULTS

Testis Explant Assay
Optimization. Experiments were conducted to optimize the culture conditions for the testis explant assay. The parameters examined were incubation time, incubation vessel, amount of tissue, FCS (+/-), hCG concentration, type of culture medium, bovine serum albumin (+/-), and addition of soybean trypsin inhibitor. A time-course experiment (1, 2, 3, 4, and 5 h) was conducted to assess the linearity of T and E2 production. T production was linear through 4 h (Fig. 1A) , while E2 production was linear through 5 h (Fig. IB) . A 3-h incubation time was used in subsequent experiments to insure that steroid production was linear over time. As expected, hCG stimulated T production, but not E2 production ( Fig. 1 ). An hCG doseresponse experiment (0, 0.01, 0.1, 1.0, and 10 IU/ml) was conducted to determine the concentration of hCG that produced maximal T production. Maximal T production was obtained at a concentration of 1.0 IU/ml hCG (Fig. 2) ; this concentration was used in all subsequent experiments. Similar to Fig. 1 , E2 production was not affected by increasing concentrations of hCG (data not shown).
Addition of FCS to the culture medium was necessary for the measurement of E2 (Table 1) . To ensure that there were no measurable amounts of T and E2 in the culture medum, the culture medum containing FCS was assayed for T and E2; none was detected (data not shown). Inclusion of FCS in the medium did not affect T production (Table 1 ). Other investigators have used quartered testis explants (300-400 mg) in their experiments (Gray et ai, 1995; Laskey et al, 1994) . In order to incorporate this assay into our ongoing Tier I battery, it was necessary to reduce the size of the testis explants; therefore, steroid production was compared using tissue amounts of 50 and 200 mg. T and E2 production was not significantly different between 50-and 200-mg explants (Table 1) ; hence, 50 mg of testicular parenchyma were used in all subsequent experiments. Surprisingly, the incubation vessel was a critical factor for the testis explant assay. hCG-stimulated explants cultured in 20-ml glass scintillation vials produced approximately 9 ii \*.
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OJO. times more T and 3.6 times more E2 than explants cultured in 16 X 100-mm borosilicate glass tubes (Table 1) . Based on the above experiments, the optimized assay conditions (which allow maximal hCG stimulation of T production) used for the compound evaluation experiments were as follows: RPMI1640 medium without phenol red, 10% FCS, 50 jig/ml medium soybean trypsin inhibitor, 50 mg testis, 1.0 IU hCG/ml medium, and a 3-h incubation time. The incubation medium (M-199 versus RPMI 1640), inclusion of bovine serum albumin, or the addition of soybean trypsin inhibitor is not critical to steroid production (data not shown). RPMI 1640 medium was selected to be consistent with the Leydig cell isolation procedure used in this laboratory (Biegel et ai, 1993) .
Compound evaluation. Following the optimization of the testis explant assay, effects of the test compounds on steroid biosynthesis were evaluated both ex vivo and in vitro. Results from the ex vivo experiments can be found in Table 2 . 17/3-E2 (0.0075 and 0.05 mg/kg/day) inhibited T production (48 and 10% of control, respectively). ANA (0.75 and 1.5 mg/kg/day) inhibited E2 production (63 and 74% of control, respectively) and had no effect on T production. FLUT (20 mg/kg/day) increased T and E2 production (217 and 121% of control, respectively). RES (0.75 and 1 mg/kg/day) decreased T production (60 and 23% of control, respectively) and E2 production (64 and 40% of control, respectively). ICI, KETO, FIN, and HALO had no effect on either T or E2 production ex vivo.
In nine in vitro experiments with testis explants, hCGstimulated T production was increased from 1.6-to 5.4-fold when compared to unstimulated explants; the mean fold increase in hCG-stimulated T production was 4.0 ± 0.5 (Table  3 ). The responses observed in the in vitro experiments (Table  3 ) differed from those observed in the ex vivo evaluation (Table  2) . ICI had no effect on T production, but increased E2 production at 0.1, 1, and 10 /xM (183, 391, and 878% of control, respectively). ANA inhibited T production at 100 JIM (57% of control), but surprisingly had no effect on E2 production. AG decreased T production at 100 and 1000 /xM (46 and 16% of control, respectively) and had no effect on E2 production. KETO decreased T production at 1 and 10 /xM (45 and 9% of control, respectively), but had no effect on E2 production. FIN decreased T and E2 production at 10 and 100 /xM (68 and 16% and 73 and 16% of control, respectively). HALO inhibited T production in a dose-dependent manner with the greatest decrease at 100 /xM (28% of control), but did not affect E2 production. 17/3-E2, FLUT, and RES had no effect on T or E2 production in vitro.
Leydig Cell Cultures
HALO, ICI, and ANA were examined using Leydig cell cultures. The concentrations of each test compound used were 0 (±hCG), 0.1, 1, 10, and 100 ;xM (all + hCG). Similar to the testis explants, HALO decreased T production in a dosedependent manner (Table 4) . Cytotoxicity was noted only at the 100 /xM concentration (Control, 95.0% viable cells, 100 /xM; HALO, 70.6%). ICI did not produce cytotoxicity and, similar to the testis explants, increased E2 production in a dose-dependent manner (Table 4) . ANA produced cytotoxicity at the three highest concentrations (Control, 98.5% viable cells; Treated, 60.0-75.2%), yet did not affect E2 or T production (Table 4) .
Ovary Explant Assay
Optimization. One goal of these studies was to make the ovary explant conditions as similar as possible to the optimized testis explant conditions to facilitate target organ toxicity comparisons. Initial experiments compared hormone production from ovaries obtained on different gestation days, left versus right fetus numbers, ovary weights, and hormone production, as well as culture vessels and stimulant (hCG, FSH, and 8-bromo-cAMP).
Hormone production was evaluated on gd 8, 12, and 17. The highest production of E2 (Fig. 3A) and P4 (Fig. 3B ) was seen on gd 8. AG (1000 /iM) inhibited E2 production on gd 8 (21% of control) and gd 12 (44% of control), but not on gd 17. P4 production was inhibited by AG on on gd 8, 12, and 17 (3, 3, and 14% of control, respectively) . In all subsequent experiments, ovaries from rats on gd 8 were evaluated. There were no differences in the number of fetuses in the left and right uterine horns, in left and right ovary weights, or in left and right ovary hormone production (Table 5 ). Based on these data, the left ovary was used as the unstimulated control and the right ovary was stimulated with hCG. Hence, these conditions allowed a similar experimental study design to the testis explants, where (+/-) hCG stimulation was evaluated using the same animal.
In examining the effect of incubation vessel on ovary explant hormone production, P4 production was similar between microfuge tubes and scintillation vials, but E2 production was almost six-fold higher in microfuge tubes (25.3 ± 5.73 versus 4.4 ± 0.63 pg/mg/h). Microfuge tubes were chosen as the incubation vessel for subsequent studies. hCG, FSH, and 8-bromo-cAMP were examined for their ability to stimulate E2 and P4 production. hCG produced less than two-fold increases in E2 production and approximately two-to threefold increased in P4 production (Tables 6 and 7) . To determine if hCG produced the maximal stimulation of steroid production, FSH and 8-bromo-cAMP were also examined. FSH, which normally stimulates granulosa cells to synthesize E2, did not affect E2 production, but did produce a dose-dependent increase in P4 production (data not shown). 8-Bromo-cAMP, at concentrations up to 10 mM, did not in- crease E2 production and increased P4 production to the same level as 1.0 IU/ml hCG (data not shown). Neither factor appeared to be better than hCG in terms of hormone stimulation; thus, hCG was used in the remaining experiments.
Compound evaluation. hCG stimulated P4 production to a similar extent in both ex vivo and in vitro experiments (approximately 2.4 ± 0.13-fold) (Tables 6 and 7) . Ex vivo, ICI had no effect on P4 production (Table 6) . Similar to what was seen in the testis explants, ICI increased E2 production in a dosedependent manner, with the greatest increase in the 1 mg/kg/ day dose group (246% of control) (Table 6 ). ANA inhibited P4 production in a dose-dependent manner, with the greatest decrease in the 10 mg/kg/day dose group (31% of control), and inhibited E2 production at 10 mg/kg/day (32% of control) (Table 6) .
In vitro, ICI increased E2 production at 10 /xM (273% of control) and decreased P4 production at 1 and 10 /xM (44 and 64% of control) (Table 7) . Surprisingly, ANA did not affect E2 or P4 production (Table 7) . AG inhibited E2 production at 10 and 100 /iM (23 and 16% of control, respectively) and also decreased P4 production at 10 and 100 /xM (69 and 21% of control, respectively). HALO did not affect either E2 or P4 production (Table 7) .
Spectral Binding Assays
The profile for a Type I spectra is a peak at 390 nm and a trough at 420 nm, while the profile for a Type II spectra is a peak at 430 nm and a trough at 390 nm. Both HALO (peak, 415 nm; trough, 385 nm) and RES (peak, 415 nm; trough, 390 nm) exhibited Type II binding spectra, indicating that both HALO and RES bind to the heme iron of cytochrome P450 to inhibit enzyme activity (data not shown).
DISCUSSION
Testis and ovary explant assays have been proposed as in vitro screens to primarily identify potential steroid biosynthesis inhibitors. The testis explant assay is designed primarily to identify T biosynthesis inhibitors, while the ovary explant assay is designed to detect aromatase inhibitors (Gray et al, 1997) . The goals of the current study were to optimize the assay procedures, to evaluate whether the testis explant assay could also detect aromatase inhibitors, and to validate these systems using several compounds with well-defined endocrine activity in order to evaluate their utility as test systems for screening unknown compounds for possible steroid biosynthesis inhibition activity.
Optimization
For the testis explant assay, the following parameters were evaluated: incubation time, incubation vessel, amount of tissue, incubation medium, FCS (+/-), and hCG concentration. Of these six parameters, the most critical component was the incubation vessel. To obtain consistent hCG stimulation of T biosynthesis, 20 ml scintillation vials must be used rather than glass test tubes (16 X 100 mm). The size of the incubation vessel may have been critical because the 20-ml scintillation vial allows greater physical dispersion of the explants. The 20-ml scintillation vial allows approximately two times as much dispersion as the 16 X 100-mm test tubes. Inclusion of FCS into culture medium was necessary for measurement of E2 by RIA, presumably by the presence of serum binding proteins. Measurement of medium E2 levels from testis explants is beneficial since it may facilitate detection of aromatase inhibitors using testis explants and therefore eliminate the need for the ovary assay. Consistent with previous work (Biegel et al., 1995) , hCG does not stimulate E2 production. The inability to enhance estradiol biosynthesis is presumably due to the substrate (i.e., testosterone) not being rate limiting based on the apparent K m for aromatase of 40 nM (Hutchison et al., 1997) . To incorporate the testis assay into our ongoing Tier I battery, it was necessary to use smaller explants than previously described in the literature (quartered testis) Gray et al., 1995) . The 50-mg testis explants had T production (0.9 ng/mg/h) that was approximately twofold greater than quartered testis (0.4-0.5 ng/mg/h) Gray et al., 1995) , demonstrating that smaller explants can be used. Note, i , decrease; t. increase; -, no change; ND, not determined. " Although no change in estradiol production was expected, the decrease is consistent with the activity of ANA; thus, the assay was considered predictive. * Although no change in testosterone production was expected, the decreases are supported because HAL exhibited a Type II binding spectra; thus, the assay was considered predictive.
c Although no change in testosterone production was expected, the ability of RES to produce Type II binding spectra suggests that testosterone production should have been decreased; thus, the assay was considered not predictive.
The goal of the ovary explant assay optimization was to optimize the conditions for detecting aromatase inhibitors and also to make the assay as similar as possible to the testis explant assay in order to facilitate target-organ toxicity comparisons. In the current studies, ovaries from pregnant rats were chosen because steroid production is more predictable on a given day of gestation and not subject to the fluctuations seen in cycling female rats (Piasek and Laskey, 1994; Gray et al, 1997) . Gestation day 8 was chosen since there is a higher level of E2 production early in gestation, and this will facilitate the detection of compounds that inhibit E2 production. By eliminating the need for monitoring of estrous cycle, the variability, complexity, and cost of this assay were reduced. One of the limitations of using ovaries from time-pregnant rats is that estradiol production is lower than in rats sacrificed in proestrus. Similar to the testis assay, the incubation vessel was important for optimal steroid (E2) production. For the ovary explant assay, the use of 1.5-ml microfuge tubes lying horizontal produced the greatest E2 production, again, probably due to the greater physical dispersion than was obtained with 20-ml scintillation vials. Because left and right ovary steroid production was found to be equivalent, an experimental design similar to the testis explant assay was used, where the left ovary was unstimulated and the right ovary was stimulated with hCG. Using this experimental design, side-by-side (+/-) hCG stimulation of ovaries produced a 2.4-fold increase in P4 production, whereas other investigators did not observe stimulation of P4 production (Piasek and Laskey, 1994) . In all likelihood, this difference is due to a different experimental design where the non-hCG incubation was conducted in the first hour, and compared to subsequent hCG stimulation in the second, third, and fourth hours.
Compound Evaluation
Responses of the testis and ovary explants to each test compound were compared to the responses observed in the Tier I male battery (O'Connor et al, 1998a,b) , as well as the published literature, in order to determine the predictability of the testis and ovary assays for identifying steroid biosynthesis inhibitors. Predictability was determined by consistency of the responses seen with the explants versus the well-characterized activity of the endocrine controls. Summaries of the predicted and observed responses can be found in Tables 8 and 9. 17/3-E2 (estrogen receptor agonist) produced a decrease in T production in ex vivo testis explants, but not in vitro. The ex vivo decrease in T production is most likely due to a combination of Leydig cell atrophy (O'Connor et al., 1998a) and downregulation of the C ]7a -hydroxylase enzyme (Nishihara et al, 1988) . Using isolated Leydig cells, 17/3-E2 does not produce a decrease in T production in vitro until 3 days of culture (Tsai-Morris et al., 1986; Nishihara et al, 1988) ; hence, 17/3-E2 would not be expected to produce a decrease in T production in vitro under the current study design, which uses a 3-h incubation. In the in vivo Tier I male battery, 17/3-E2 produced a dose-dependent decrease in serum T, DHT, and LH levels (O'Connor et al, 1998a) , consistent with the ex vivo findings.
ICI was predicted to be a negative control in the testis and ovary explant assays because it had no effect in the in vivo Tier Note, i , decrease; f, increase; -, no change; ND, not determined. " Although no change in hormone production was expected, the decreases are consistent with the activity of ANA; thus, the assay was considered predictive.
I battery (O'Connor et al, 1998b) and since its endocrine activity is characterized as a pure estrogen receptor antagonist (Wakeling et al, 1991) . ICI did not affect ex vivo steroid production, yet it unexpectedly increased E2 production by testis explants in vitro (8.8-fold compared to the hCG control). When isolated Leydig cells were cultured with identical concentrations of ICI, E2 production was similarly increased in a dose-dependent manner. Furthermore, an increase in E2 production was seen in both ex vivo and in vitro ovary explants. This paradoxical response is not consistent with in vivo findings (Wakeling et al, 1991; O'Connor et al, 1998b) , and the mechanism is unclear. One possibility is that ICI may interfere with the E2 RIA; however, no interference was detected when medium containing ICI was examined in the E2 RIA by using ICI-spiked calibrators with known concentrations of E2 (data not shown). The implication is that the effective concentrations of ICI were sufficient to elicit an agonistic response through a local feedback loop that stimulates E2 production.
ANA is a potent and highly selective aromatase inhibitor with no intrinsic hormonal activities (Dukes et al, 1996) . It was expected that ANA would inhibit E2 production and have no effect on T production. This pattern of responses was seen in the Tier I male battery (O'Connor et al, 1998b) and in the ex vivo testis explant assay. However, in vitro T production was inhibited and there was no effect on E2 production. The inability to detect ANA as an aromatase inhibitor in the in vitro testis explant assay probably reflects the low aromatase activity within the testis. Furthermore, when isolated Leydig cells were exposed to ANA, T and E2 production were not affected. ANA has not been previously reported to inhibit T production, although it has been shown to inhibit other cytochrome P 450 isozymes in vitro when tested at relatively high concentrations (PDR, 1996) . In the ovary explant assay, ANA decreased both E2 and P4 production ex vivo but not in vitro. The decrease in E2 production observed ex vivo was unexpected since the ex vivo assessment is not designed to detect compounds that directly inhibit enzyme activity but is designed to identify compounds that up-or downregulate the enzymes of the steroidogenic pathway or compounds that cause atrophy or hyperplasia of Leydig, theca, or granulosa cells. The reason E2 production was not affected in vitro in the testis or ovary assay is unclear. Repeated administration of aromatase inhibitors has been shown to decrease estrogen levels by inducing estrogen metabolism (Purba et al, 1994) , which may be another means by which ANA decrease E2 ex vivo, but not in vitro. These results suggest diat both the in vitro testis and ovary explant assays are limited in their ability to detect aromatase inhibitors.
KETO is a T biosynthesis inhibitor (reviewed in Feldman, 1986) . In the testis explant assay, KETO did not affect T or E2 production ex vivo. As expected, in vitro, KETO decreased T production and had no effect on E2 production. The inability of KETO to decrease T production ex vivo has been previously shown (Kan et al, 1985; Pont et al, 1982) . The discrepancy between the in vitro and ex vivo results is attributed to the dilution of residual KETO when the testis from treated rats is placed into the culture medium, a finding consistent with enzyme inhibitors that act by directly binding to inhibit the steroidogenic pathway. In the Tier I battery, KETO lowered serum T and DHT, increased LH and FSH, and had no effect on PRL (O'Connor et al, 1998b) . Hence, there was concordance between the testis explants, the in vivo Tier I male battery, and the published literature.
AG is a mixed aromatase/C^-side chain cleavage inhibitor (Salhanick, 1982) . In the in vitro testis explant assay, AG decreased T but not E2 production, suggesting that only the C 27 -side chain cleavage enzyme is being inhibited. As expected based on published literature (Steinetz et al, 1985) , AG decreased both E2 and P4 production in the in vitro ovary explant assay. The inability to detect AG and ANA as aromatase inhibitors in the in vitro testis explant assay probably reflects the low aromatase activity within the testis.
In the testis explant assay, FIN, a 5a-reductase inhibitor, had no effect on hormone production ex vivo, but decreased T and E2 production in vitro. These data are not predicted based on the pharmacologic activity (Rittmaster, 1994) . The reason for the decrease is unclear and may be due to cytotoxicity. As-sessment of FIN in the Tier I male battery revealed decreases in serum DHT levels and increases in LH and PRL levels, which is consistent with its mode of action (O'Connor et al, 1998b) . Therefore, the data from the testis explant assay were not consistent with the expected results based on the data from the Tier I male battery (O'Connor et al, 1998b) or the published literature.
As expected, FLUT, an androgen receptor antagonist, increased T production in the ex vivo testis explant assay, but not in vitro. In the Tier I male battery, FLUT increased serum T, DHT, E2, FSH, and LH levels and produced diffuse Leydig cell hyperplasia (O'Connor et al, 1998b) . Hence, the increase in T production in the ex vivo testis explant assay is attributed to the Leydig cell hyperplasia and increased steroidogenic capacity due to hypertrophy as a result of the increased serum LH levels (Ewing and Zirkin, 1983; Wing et al, 1984; MendisHandagama et al, 1988; Cook et al, 1993) . These data demonstrate concordance between the testis explants, the in vivo Tier I male battery, and the published literature (Neri et al, 1972; Simard et al, 1986; O'Connor et al, 1998b) .
HALO, a dopamine receptor antagonist, had no effect on hormone production in the ex vivo testis explant assay or in the in vitro ovary explant assay, but inhibited T production in the in vitro testis assay. Similarly, when isolated Leydig cells were exposed to HALO in vitro, T production was inhibited in a dose-dependent manner. In the Tier I male battery, HALO increased serum PRL, but had no other effects (unpublished data). It is unclear why the decrease in T production was not observed in the ex vivo testis assay or in the Tier I battery; however, it seems possible that the dose was not high enough to inhibit T biosynthesis based on the absence of any body weight effects in the HALO-treated rats. HALO has been shown to suppress testosterone production in rats and humans, possibly via a central effect (Okonmah et al, 1986; Rinieris et al, 1990) . However, the in vitro testis explant and Leydig cell data suggest that HALO is acting directly on the Leydig cell. In support of this, HALO produced a Type II binding spectrum with cytochrome P 450 (Lewis, 1986) , confirming a direct inhibitory mechanism. These data demonstrate agreement between the testis explant assay and published literature.
RES, a dopamine depletor, inhibited both T and E2 production in the ex vivo testis explant assay. These decreases appear secondary to Leydig cell atrophy (unpublished data). Similar to HALO, RES displayed a Type II binding spectrum with cytochrome P 4J0 , suggesting that it binds to the heme iron to inhibit activity. However, in the in vitro testis explant assay, T and E2 production were not affected, suggesting that RES does not appear to be directly inhibiting testosterone biosynthesis. The reason for this discrepancy is unclear. In the Tier I male battery, RES decreased serum T, DHT, E2, LH, and FSH (unpublished data). The magnitude of the decrease in LH and FSH, coupled with die testis explant data, indicates that RES is also acting centrally. Because histopathological examination of the testis demonstrated the presence of Leydig cell atrophy, the Tier I male battery and testis explant assay data are consistent.
Conclusions
One of the goals was to determine if the testis explant assay could be used to detect aromatase inhibitors. Addition of FCS to the medium allowed measurement of E2 production by testis explants, which was not inhibited by ANA or AG. It seems likely that the failure of the testis explant assay to detect aromatase inhibitors may be due to the low aromatase activity widiLn the testis. In the ovary explant assay, only AG was identified as inhibiting E2 production in vitro. This was surprising given that the ovary has higher levels of aromatase than the testis, and ANA is a more specific aromatase inhibitor than AG (Dukes et al, 1996) . The reason ANA did not inhibit E2 production is unclear. Under the current assay conditions, the testis and ovary explant assays appear to have limited utility in detecting aromatase inhibitors.
A major limitation of the ovary and testis assays is the difficulty in assessing cytotoxicity. The decreases seen in hormone production (ANA, AG, KETO, FIN, HALO, and RES) could possibly be due to cytotoxicity, rather than a direct effect of the compound. Viability measurements in the isolated Leydig cell cultures indicated that there may be some cytotoxicity associated with exposure to ANA and high doses of HALO; however, ANA did not affect E2 production in vitro using Leydig cell cultures or the testis explants. Standard means of measuring cytotoxicity (lactate dehydrogenase production, MTT) may be confounded in these assays due to interference from the high levels of fetal calf serum (10%) as well as cell damage due to the physical dispersion from the shaking during incubation. Clearly, a reliable measure of cytotoxicity should be developed before the testis and ovary explants are used for examining unknown compounds for steroid biosynthesis inhibition activity.
The in vitro and ex vivo testis/ovary explant assays detect two different responses to EACs. The in vitro assays can potentially identify compounds that directly inhibit steroid biosynthesis, while the ex vivo assays indirectly identify compounds that produce either hyperplasia and/or atrophy of steroid-producing cells (Leydig, theca, and granulosa), secondary to altered steroid production. The in vitro testis explant assay correctly identified four of nine compounds based on published literature and the data from the Tier I in vivo battery (17/3-E2, KETO, FLUT, and HALO). For this data set, which used compounds with diverse endocrine activities, the predictability of die in vitro testis explant assay was 44%, suggesting that a false positive or negative rate of 56% could occur with unknown compounds (Table 8 ). The ex vivo testis explant assay correctly identified eight of eight compounds. Based on these results, the ex vivo testis explant assessment would give a lower false positive rate than a combination of an ex vivo/in vitro testis explant assessment. However, the ex vivo testis explant assay does not identify compounds that have the potential to directly inhibit steroid biosynthesis, but rather identifies compounds that produce either atrophy or hyperplasia of the Leydig cells, albeit indirectly. The predictability of both the in vitro and ex vivo ovary assay was 50%, suggesting a 50% false positive or negative rate with unknown compounds (Table 9). It appears from these data that the ovary explant assay will not be useful as a screening assay for identifying aromatase inhibitors based on its inability to detect ANA. The ability of the ovary explant assay to detect other types of steroid biosynthesis inhibitors has not been evaluated. In contrast, histopathology of the testis, which is included in the Tier I battery, would detect all compounds that produced Leydig cell atrophy/hyperplasia and therefore would identify potential steroid biosynthesis inhibitors. Furthermore, of the seven compounds assessed to date (17/3-E2, ICI, ANA, KETO, FLUT, HALO, and RES), all were correctly identified using the Tier I male battery, which also has the ability to detect other endocrine activities (O'Connor et al., 1998a,b) . Therefore, the testis and ovary explant assay would not be necessary if one was using an in vivo Tier I battery, since this screen would identify a steroid biosynthesis inhibitors, and would also identify several other endocrine responses. Based on the results of this study, the testis and ovary explant assays would not be useful as routine screening procedures for detecting steroid biosynthesis inhibitors. This conclusion is based on the high false positive/negative rates and the difficulties in assessing cytotoxicity. Clearly, the results of this work, coupled with our ongoing validation of a Tier I screening battery (O'Connor et al., 1998a,b) , suggest that in vivo models should be used to identify EACs, followed by confirmation in either in vitro or definitive tests such as a multigeneration reproduction study.
